25

WHAT IS CLAIMED IS:

1. A glycopeptide compound having at least one substituent of the formula:

$$-R^a-Y-R^b-(Z)_x$$

5 wherein

each R^a is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkynylene and substituted alkynylene;

bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene, provided R^b is not a covalent bond when Z is hydrogen;

each Y is independently selected from the group consisting of oxygen, sulfur, -S-S-, -NR^c-, -S(O)-, -SO₂-, -NR^cC(O)-, -OC(O)-, -NR^cSO₂-, -OSO₂-, -C(O)NR^c-, -C(O)O-, -SO₂NR^c-, -SO₂O-, ,-P(O)(OR^c)O-, -P(O)(OR^c)NR^c-, -OP(O)(OR^c)O-, -OP(O)(OR^c)NR^c-, -OC(O)O-, -NR^cC(O)O-, -NR^cC(O)NR^c-, -OC(O)NR^c- and -NR^cSO₂NR^c-; each Z is independently selected from hydrogen, aryl, cycloalkyl,

cycloalkenyl, heteroaryl and heterocyclic;

each R^c is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and -C(O)R^d;

each R^d is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl,

15

cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

x is 1 or 2;

and pharmaceutically acceptable salts thereof;

5 provided that:

- (i) when Y is -NR^c-, R^c is alkyl of 1 to 4 carbon atoms, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;
- (ii) when Y is -C(O)NR^c-, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;
- (iii) when Y is sulfur, Z is hydrogen and R^b is alkylene, then R^b contains at least 7 carbon atoms; and
- (iv) when Y is oxygen, Z is hydrogen and R^b is alkylene, then R^b contains at least 11 carbon atoms.
- 2. The compound of Claim 1, wherein the glycopeptide compound is substituted with from 1 to 3 substituents of the formula $-R^a-Y-R^b-(Z)_x$.
 - 3. The compound of Claim 2, wherein each Ra is independently selected from alkylene having from 1 to 10 carbon atoms.
 - 4. The compound of Claim 3, wherein Ra is ethylene or propylene.
- 5. The compound of Claim 2, wherein Z is hydrogen and R^b is alkylene of from 8 to 12 carbon atoms.
 - 6. The compound of Claim 5, wherein R^b and Z form an n-octyl, n-nonyl, n-decyl, n-undecyl or n-dodecyl group.

- 7. The compound of Claim 2, wherein Z is aryl, cycloalkyl, cycloalkenyl, heteroaryl or heterocyclic and R^b is a covalent bond or alkylene of from 1 to 10 carbon atoms.
- 8. The compound of Claim 7, wherein Z is aryl and R^b is a covalent bond, methylene, $-(CH_2)_6$, $-(CH_2)_7$, $-(CH_2)_8$, $-(CH_2)_9$ or $-(CH_2)_{10}$.
 - 9. The compound of Claim 2, wherein each Y is independently selected from the group consisting of oxygen, sulfur, -S-S-, -NR^c-, -S(O)-, -SO₂-, -NR^cC(O)-, -OC(O)-, -NR^cSO₂-, -C(O)NR^c-, -C(O)O- and -SO₂NR^c-.
- 10. The compound of Claim 9, wherein Y is oxygen, sulfur, -NR^c- or -NR^cSO₂-.
 - 11. The compound of Claim 2, wherein each Z is independently selected from hydrogen, aryl, cycloalkyl, heteroaryl and heterocyclic.
 - 12. The compound of Claim 11, wherein Z is hydrogen or aryl.
- 13. The compound of Claim 12, wherein Z is phenyl, substituted phenyl, biphenyl, substituted biphenyl or terphenyl.
 - 14. The compound of Claim 2, wherein the $-R^a-Y-R^b-(Z)_x$ group is selected from the group consisting of:

$$-CH2CH2-NH-(CH2)9CH3;$$

$$-CH_2CH_2CH_2-NH-(CH_2)_8CH_3;$$

$$-CH_2CH_2-NHSO_2-(CH_2)_9CH_3$$
;

```
TI THE LIM
II.
TI
```

```
-CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>-(CH<sub>2</sub>)<sub>11</sub>CH<sub>3</sub>;
                    -CH_2CH_2-S-(CH_2)_8CH_3
                    -CH_2CH_2-S-(CH_2)_9CH_3
                    -CH_2CH_2-S-(CH_2)_{10}CH_2;
 5
                    -CH_2CH_2CH_2-S-(CH_2)_8CH_3;
                    -CH_2CH_2CH_2-S-(CH_2)_9CH<sub>3</sub>;
                    -CH_2CH_2CH_2-S-(CH_2)_3 -CH=CH-(CH_2)_4CH_3 (trans);
                    -CH_2CH_2CH_2CH_2-S-(CH_2)_7CH_3;
                   -CH_2CH_2-S(O)-(CH_2)_9CH_3;
10
                    -CH_2CH_2-S-(CH_2)_6Ph;
                    -CH_2CH_2-S-(CH_2)_8Ph_2
                    -CH_2CH_2CH_2-S-(CH_2)_8
                    -CH<sub>2</sub>CH<sub>2</sub>-NH-CH<sub>2</sub>-4-(4-C)-Ph)-Ph;
                   -CH<sub>2</sub>CH<sub>2</sub>-NH-CH<sub>2</sub>-4-[H<sub>3</sub>)<sub>2</sub>CHCH<sub>2</sub>-]-Ph;
15
                   -CH<sub>2</sub>CH<sub>2</sub>-NH-CH<sub>2</sub>4-(4-CF<sub>3</sub>-Ph)-Ph;
                    -CH_2CH_2-S-CH_2-4-(4/CI-Ph)-Ph;
                   -CH_2CH_2-S(O)-CH_2-4-(4-C1-Ph)-Ph;
                    -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph;
                    -CH_2CH_2-S(O)-CH_2+4-(4-Cl-Ph)-Ph;
20
                    -CH_2CH_2CH_2-S-CH_2-4-[3,4-di-Cl-PhCH_2O-)-Ph;
                    -CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>-CH<sub>2</sub>-4-[4-(4-Ph)-Ph]-Ph;
                    -CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph;
                    -CH_2CH_2CH_2-NHSO_2-CH_2-4-(Ph-C \equiv C-)-Ph;
                    -CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>-4-(4-Cl-Ph)-Ph; and
                    -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>-4-(naphth-2-yl)-Ph.
25
```

10

15

A compound of formula I:

15. A compound of formula I:

$$R^2 O \longrightarrow R^{13} \longrightarrow R^{13} \longrightarrow R^{11} \longrightarrow R^{12} \longrightarrow R^{13} \longrightarrow R^{14} \longrightarrow R^{15} \longrightarrow$$

--145--

R1 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and $-R^a-Y-R^b-(Z)_x$ or a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)$;

R² is hydrogen or a saccharide group optionally substituted with $-R^{a}-Y-R^{b}-(Z)_{x};$

 R^3 is $-OR^c$, $-NR^cR^c$, $-O-R^{a}-Y-R^b-(Z)_x$, $-NR^c-R^a-Y-R^b-(Z)_x$, $-NR^cR^c$, or -O-Re;

R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, $-R^a-Y-R^b-(Z)_x$, $-C(O)R^d$ and a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$;

R⁵ is selected from the group consisting of hydrogen, halo, $-CH(R^c)-NR^cR^c, -CH(R^c)-NR^cR^e \text{ and } -CH(R^c)-NR^c-R^a-Y-R^b-(Z)_x;$

 R^6 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, $-R^a-Y-R^b-(Z)_x$, $-C(O)R^d$ and a saccharide group optionally substituted with $-NR^c-R^a-Y-R^b-(Z)_x$, or R^5 and R^6 can be joined, together with the atoms to which they are attached, form a heterocyclic ring optionally substituted with $-NR^c-R^a-Y-R^b-(Z)_x$;

 R^7 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, $-R^a-Y-R^b-(Z)_x$, and $-C(O)R^d$;

R⁸ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R⁹ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R¹⁰ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic; or R⁸ and R¹⁰ are joined to form -Ar¹-O-Ar²-, where Ar¹ and Ar² are independently arylene or heteroarylene;

R¹¹ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic, or R¹⁰ and R¹¹ are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring;

15

20

25

10

10 -

15

20

25

 R^{12} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, $-C(O)R^d$, $-C(NH)R^d$, $-C(O)NR^cR^c$, $-C(O)OR^d$, $-C(NH)NR^cR^c$ and $-R^a-Y-R^b-(Z)_x$, or R^{11} and R^{12} are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring;

R¹³ is selected from the group consisting of hydrogen or -OR¹⁴;

R¹⁴ is selected from hydrogen, -C(O)R⁴ and a saccharide group;
each R^a is independently selected from the group consisting of alkylene,
substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene;

each R^b is independently selected/from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene provided R^b is not a covalent bond when Z is hydrogen;

each R^c is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heterocyclic and $-C(\Phi)R^d$.

each R^d is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

Re is a saccharide group;

X¹, X² and X³ are independently selected from hydrogen or chloro; each Y is independently selected from the group consisting of oxygen, sulfur, -S-S-, -NR^c-, -S(O)-, -SO₂-, -NR^cC(O)-, -OSO₂-, -OC(O)-, -NR^cSO₂-, -C(O)NR^c-, -C(O)O-, -SO₂NR^c-, -SO₂O-, -P(O)(OR^c)O-,

-P(O)(OR°)NR°-, -OP(O)(OR°)O-,-OP(O)(OR°)NR°-, -OC(O)O-,
-NR°C(O)O-, -NR°C(O)NR°-, -OC(O)NR°- and -NR°SO₂NR°-;
each Z is independently selected from hydrogen, aryl, cycloalkyl,
cycloalkenyl, heteroaryl and heterocyclic:

n is 0, 1 or 2;

x is 1 or 2;

and pharmaceutically acceptable salts, stereoisomers and prodrugs thereof; provided that at least one of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 or R^{12} has a substitutent of the formula $-R^a-Y-R^b-(Z)_{x^6}$

and further provided that:

- (i) when Y is -NR^c-, R^c is alkyl of 1 to 4 carbon atoms, Z is hydrogen and R^b is alkylene, then R^b contains/at least 5 carbon atoms;
- (ii) when Y is $-C(O)NR^{c}$, Z is hydrogen and R^{b} is alkylene, then R^{b} contains at least 5 carbon atoms;
- (iii) when Y is sulfur, Z is hydrogen and R^b is alkylene, then R^b contains at least 7 carbon atoms; and
- (iv) when Y is oxygen, Z is hydrogen and R^b is alkylene, then R^b contains at least 11 carbon atoms.
- 16. The compound of Claim 15, wherein R^1 is a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$.
 - 17. The compound of Claim 16, wherein R¹ is a saccharide group of the formula:

10

5

15

wherein

 R^{15} is $-R^a - Y - R^b - (Z)_x$; and

R¹⁶ is hydrogen or methyl.

The compound of Claim 17, wherein R^{15} is a $-R^a-Y-R^b-(Z)_x$ group 18.

selected from the group consisting of: 5

 $-CH_2CH_2-NH-(CH_2)/CH_3$;

-CH2CH2CH2-NH-(4)2/8CH3;

-CH₂CH₂CH₂-NH (CH₂) CH₃;

-CH₂CH₂-NHSO₂-(CH₂)₉CH₃

-CH₂CH₂-NHSO₂/(CH₂)₁₁CH₃ 10

-CH₂CH₂-S-(CH₂),CH₃;

-CH₂CH₂-S-(CH₂)₉CH₃;

 $-CH_2CH_2-S-(CH_2)_{10}CH_3;$

 $-CH_2CH_2CH_2-S-(CH_2)$ CH_3 ;

15 -CH₂CH₂CH₂-S-(CH₂)₉CH₃;

 $-CH_2CH_2CH_2-S-(CH_2)_3$ CH = CH-(CH₂)₄CH₃ (trans);

-CH₂CH₂CH₂CH₂-S-(CH₂)₇CH₃;

 $-CH_2CH_2-S(O)-(CH_2)_9CH_3;$

 $-CH_2CH_2-S-(CH_2)_6Ph;$

```
-150--
                          -CH_2CH_2-S-(CH_2)_8Ph;
                          -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>8</sub>Ph;
                         -CH<sub>2</sub>CH<sub>2</sub>-NH-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph;
                         -CH<sub>2</sub>CH<sub>2</sub>-NH-CH<sub>2</sub>-4-[4-CH<sub>3</sub>)<sub>2</sub>CHCH<sub>2</sub>-]-Ph;
    5
                         -CH<sub>2</sub>CH<sub>2</sub>-NH-CH<sub>2</sub>-4-(4-CF<sub>3</sub>-Ph)-Ph;
                         -CH<sub>2</sub>CH<sub>2</sub>-S-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph;
                         -CH<sub>2</sub>CH<sub>2</sub>-S(O)-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph;
                         -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph;
                        -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S(O)-CH<sub>2</sub>-4-(4-Q1-Ph)-Ph;
                        -CH<sub>2</sub>CH<sub>2</sub>-S-CH<sub>2</sub>-4-[3,4-di-Cl-PhCH<sub>2</sub>O-)-Ph;
 10
                        -CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>-CH<sub>2</sub>-4-[4-(4-Ph)-Ph]-Ph]
                        -CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>/CH<sup>2</sup>/4-(4-Cl-Ph)-Ph;
                        -CH_2CH_2CH_2-NHSO/-CH/2-4/(Ph-C=C-)-Ph;
                        -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-NHSQ<sub>2</sub>-4-(4+Cl-Ph)-Ph; and
 15
                        -CH<sub>2</sub>CH<sub>2</sub>-NHS\phi_2-A-(haphth-2-yl)-Ph.
                                   The compound of Claim 15, wherein R3 is -OH or -NRCRC.
                        19.
                                   The compound of Claim 15, wherein R5 is hydrogen, -CH2-N-(N-
                       20.
            CH<sub>3</sub>-D-glucamine); -CH<sub>2</sub>-NH-CH<sub>2</sub>CH<sub>2</sub>-NH-(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>; -CH<sub>2</sub>-NH-CH<sub>2</sub>CH<sub>2</sub>-NH-
            (CH_2)_{11}CH_3; -CH_2-NH-(CH_2)_3-CO\phi H; and -CH_2-N-(2-amino-2-deoxygluconic)
20
            acid).
                       21.
```

- 21. The compound of Claim 15, wherein R⁸ is -CH₂C(O)NH₂, -CH₂COOH, benzyl, 4-hydroxyphenyl or 3-chloro-4-hydroxyphenyl.
- 22. The compound of Claim 15, wherein R^9 is hydrogen and R^{11} is hydrogen or methyl.

10

23. The compound of Claim $2^{\frac{1}{2}}$, wherein R^{10} is alkyl or substituted alkyl.

--1517--

24. The compound of Claim 23, wherein R^{12} is hydrogen, alkyl, substituted alkyl or $-C(O)R^d$.

25. The compound of Claim 24, wherein n is 1.

26. A compound of formula II:

HO
$$R^{26}$$
 R^{26}
 R^{27}
 R^{22}
 R^{23}
 R^{23}
 R^{23}
 R^{24}
 R^{25}
 R^{27}
 R^{27}
 R^{27}

 R^{21} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and $-R^a-Y-R^b-(Z)_x$; or a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$;

10

15

20

25

 R^{22} is $-OR^c$, $-NR^cR^c$, $-O-R^a-Y-R^b-(Z)_x$ or $-NR^c-R^a-Y-R^b-(Z)_x$; R^{23} is selected from the group consisting of hydrogen, halo, $-CH(R^c)-NR^cR^c$, $-CH(R^c)-R^c$ and $-CH(R^c)-NR^c-R^a-Y-R^b-(Z)_x$; R^{24} is selected from the group consisting of hydrogen and lower alkyl;

R²⁵ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R²⁶ is selected from the group consisting of hydrogen and lower alkyl; or R²⁵ and R²⁶ are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring;

 R^{27} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, $-C(O)R^d$, $-C(NH)R^d$, $-C(O)NR^cR^c$, $-C(O)OR^d$, $-C(NH)NR^cR^c$ and $-R^a-Y-R^b-(Z)_x$, or R^{26} and R^{27} are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring;

each R^a is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkynylene and substituted alkynylene;

each R^b is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene, provided R^b is not a covalent bond when Z is hydrogen;

each R^c is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and $-C(\Phi)R^d$;

10

15

25

each R^d is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

Re is an aminosaccharide group;

each Y is independently selected from the group consisting of oxygen, sulfur, $-S-S-,-NR^c-,-S(O)-,-SO_2-,-NR^cC(O)-,-OSO_2-,-OC(O)-,$

$$-NR^{c}SO_{2}^{-}$$
, $-C(O)NR^{c}$, $-C(O)O^{-}$, $-SO_{2}NR^{c}$, $-SO_{2}O^{-}$, $-P(O)(OR^{c})O^{-}$,

$$-P(O)(OR^c)NR^{c-}$$
, $-OP(O)(OR^c)O^{\frac{1}{2}}$, $-OP(O)(OR^c)NR^{c-}$, $-OC(O)O^{-}$,

 $-NR^{c}C(O)O-$, $-NR^{c}C(O)NR^{c}-$, $-OC(O)NR^{c}-$ and $-NR^{c}SO_{2}NR^{c}-$;

each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic;

n is 0, 1 or 2;

x is 1 or 2;

and pharmaceutically acceptable salts, stereoisomers and prodrugs thereof; provided that at least one of R^{21} , R^{22} , R^{23} or R^{27} has a substitutent of the formula $-R^a-Y-R^b-(Z)_x$;

and further provided that:

- (i) when Y is -NR^c-, R is alkyl of 1 to 4 carbon atoms, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;
 - (ii) when Y is -C(O)NR^c-, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;
 - (iii) when Y is sulfur, Z is hydrogen and R^b is alkylene, then R^b contains at least 7 carbon atoms; and
 - (iv) when Y is oxygen, Z is hydrogen and R^b is alkylene, then R^b contains at least 11 carbon atoms.
 - 27. The compound of Claim 26, wherein \mathbb{R}^{21} is a saccharide group of the formula:

wherein

 R^{15} is $-R^a-Y-R^b-(Z)_x$, and

R¹⁶ is hydrogen or methyl.

28. The compound of \mathbb{Z} laim 27, wherein \mathbb{R}^{15} is a $-\mathbb{R}^a - \mathbb{Y} - \mathbb{R}^b - (\mathbb{Z})_x$ group

5 selected from the group consisting of

-CH₂CH₂-NH-(CH₂)₉CH₃;

 $-CH_2CH_2CH_2-NH-(QH_2)_8CH_3$

-CH₂CH₂CH₂CH₂-NH-(CH₂), CH₃;

-CH₂CH₂-NHSO₂-(CH₂)₉CH₃;

10 -CH₂CH₂-NHSO₂-(CH₂)₁₁CH₃;

-CH₂CH₂-S-(CH₂) CH₃

-CH₂CH₂-S-(CH₂) CH₃

-CH₂CH₂-S-(CH₂)₁₀CH₃;

-CH₂CH₂-S-(CH₂)₈CH₃;

15 $-CH_2CH_2CH_2-S-(CH_2)_9CH_3$;

 $-CH_2CH_2CH_2-S-(CH_2)_3-CH=CH-(CH_2)_4CH_3$ (trans);

 $-CH_2CH_2CH_2CH_2-S-(CH_2)_7CH_3;$

 $-CH_2CH_2-S(O)-(CH_2)_9CH_9;$

 $-CH_2CH_2-S-(CH_2)_6Ph;$

 $-CH_2CH_2-S-(CH_2)_8Ph;$

```
-CH_2CH_2CH_2-S-(CH_2)_8Ph;
```

- -CH₂CH₂-NH-CH₂-4-(4-Cl-Ph)-Ph;
- -CH₂CH₂-NH-CH₂-4-[4-CH₃)₂CHCH₂-]-Ph;
- $-CH_2CH_2-NH-CH_2-4-(4-CF_3-Ph)-Ph;$
- 5 $-CH_2CH_2-S-CH_2-4-(4-Cl-Ph)-Ph$;
 - $-CH_2CH_2-S(O)-CH_2-4-(4-Cl-Ph)-Ph;$
 - $-CH_2CH_2CH_2-S-CH_2-4-(4-cl-Ph)-Ph;$
 - -CH₂CH₂CH₂-S(O)-CH₂-4-(4-Cl-Ph)-Ph;
 - -CH₂CH₂CH₂-S-CH₂-4-[3,4|di-Cl-PhCH₂O-)-Ph;
- $-CH_2CH_2-NHSO_2-CH_2-4-[4](4-Ph)-Ph]-Ph;$
 - -CH₂CH₂CH₂-NHSO₂-CH₂-4-(4-¢/1-Ph)-Ph;
 - $-CH_2CH_2CH_2-NHSO_2-CH_2-4-(Ph-C=C-)-Ph;$
 - -CH₂CH₂CH₂-NHSO₂-4-(4-CPh)-Ph; and
 - -CH₂CH₂CH₂-NHSO₂-4-(naphth-2-yl)-Ph.
 - 29. The compound of Claim 26, wherein R²² is -OH or -NR^cR^c.
 - 30. The compound of Claim 26, wherein R²³ is hydrogen, -CH₂-N-(N-CH₃-D-glucamine); -CH₂-NH-CH₂CH₂-NH-(CH₂)₉CH₃; -CH₂-NH-CH₂CH₂-NH-(CH₂)₁₁CH₃; -CH₂-NH-(CH₂)₅-COOH; or -CH₂-N-(2-amino-2-deoxygluconic acid).
- 31. The compound of Claim 26, wherein R²⁴ is hydrogen and R²⁶ is hydrogen or methyl.
 - 32. The compound of Claim 31, wherein R^{25} is alkyl or substituted alkyl.
 - 33. The compound of Claim 32, wherein R²⁵ is isobutyl.

- 34. The compound of Claim 33, wherein R^{27} is hydrogen, alkyl, substituted alkyl or $-C(O)R^d$.
- 35. A compound shown in any of Tables I, II, III, IV, V or VI, or a pharmaceutically-acceptable salt thereof.
- 36. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of a glycopeptide compound having at least one substituent of the formula:

$$-R^a-Y-R^b-(Z)$$

20

25

wherein

each R^a is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkynylene and substituted alkynylene;

bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene, provided R^b is not a covalent bond when Z is hydrogen;

each Y is independently selected from the group consisting of oxygen, sulfur, -S-S-, $-NR^c-$, -S(O)-, $-SO_2-$, $-NR^cC(O)-$, -OC(O)-, $-NR^cSO_2-$, $-OSO_2-$, $-C(O)NR^c-$, -C(O)O-, $-SO_2NR^c-$, $-SO_2O-$, $-P(O)(OR^c)O-$,

$$-P(O)(OR^c)NR^c - , -OP(O)(OR^c)O - , -OP(O)(OR^c)NR^c - , -OC(O)O - , -OP(O)(OR^c)NR^c - , -OP(O$$

-NR°C(O)O-, -NR°C(O)NR°-, -OC(O)NR°- and -NR°SO₂NR°-;

each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic;

each R^c is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl,

cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and -C(O)R^d;

each R^d is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

x is 1 or 2;

and pharmaceutically acceptable salts thereof; provided that:

10

15

20

- (i) when Y is -NR^c-, R^c is alkyl of 1 to 4 carbon atoms, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;
- (ii) when Y is -C(O)NR^c-, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;
- (iii) when Y is sulfur, Z is hydrogen and R^b is alkylene, then R^b contains at least 7 carbon atoms; and
- (iv) when Y is oxygen, Z is hydrogen and R^b is alkylene, then R^b contains at least 11 carbon atoms.
- 37. The pharmaceutical composition of Claim 36, wherein the glycopeptide compound is substituted with from 1 to 3 substituents of the formula $-R^a-Y-R^b-(Z)_x$.
 - 38. The pharmaceutical composition of Claim 37, wherein each R^a is independently selected from alkylene having from 1 to 10 carbon atoms.
 - 39. The pharmaceutical composition of Claim 38, wherein R^a is ethylene or propylene.

- 40. The pharmaceutical composition of Claim 37, wherein Z is hydrogen and R^b is alkylene of from 8 to 12 carbon atoms.
- 41. The pharmaceutical composition of Claim 40, wherein \mathbb{R}^b and \mathbb{Z} form an n-octyl, n-nonyl, n-decyl, n-undecyl or n-dodecyl group.
- The pharmaceutical composition of Claim 37, wherein Z is aryl, cycloalkyl, cycloalkenyl, heteroaryl or heterocyclic and R^b is a covalent bond or alkylene of from 1 to 10 carbon atoms.
 - 43. The pharmaceutical composition of Claim 42, wherein Z is aryl and R^b is a covalent bond, methylene, $-(CH_2)_{6^-}$, $-(CH_2)_{7^-}$, $-(CH_2)_{9^-}$ or $-(CH_2)_{10^-}$.
 - 44. The pharmaceutical composition of Claim 37, wherein each Y is independently selected from the group consisting of oxygen, sulfur, -S-S-, -NR^c-, -S(O)-, -SO₂-, -NR^cC(O)-, -OC(O)-, -NR^cSO₂-, -C(O)NR^c-, -C(O)O- and -SO₂NR^c-.
- 15 45. The pharmaceutical composition of Claim 44, wherein Y is oxygen, sulfur, -NR^c- or -NR^cSO₂-.
 - 46. The pharmaceutical composition of Claim 37, wherein each Z is independently selected from hydrogen, aryl, cycloalkyl, heteroaryl and heterocyclic.
- 20 47. The pharmaceutical composition of Claim 46, wherein Z is hydrogen or aryl.

48. The pharmaceutical composition of Claim 47, wherein Z is phenyl, substituted phenyl, substituted biphenyl or terphenyl.

49. The pharmaceutical composition of Claim 37, wherein the $-R^a-Y-R^b-(Z)_x$ group is selected from the group consisting of:

```
5
                                -CH<sub>2</sub>CH<sub>2</sub>-NH-(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>;
                               -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-NH-(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub>;
                               -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-NH-(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>;
                               -CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>-(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>;
                               -CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>-(CH<sub>2</sub>)<sub>11</sub>CH<sub>3</sub>;
  10
                               -CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>8</sub>CH<sub>3</sub>;
                               -CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>;
                               -CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>10</sub>CH<sub>3</sub>;
                              -CH_2CH_2CH_2-S-(CH_2)_8CH_3';
                              -CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>
                              -CH_2CH_2CH_2-S-(CH_2)_3-\psi H \not\vdash CH-(\partial H_2)_4CH_3 \ (trans);
 15
                              -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)/CH
                              -CH<sub>2</sub>CH<sub>2</sub>-S(O)-(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>;
                              -CH_2CH_2-S-(CH_2)_6Ph;
                              -CH_2CH_2-S-(CH_2)_8Ph;
20
                              -CH_2CH_2CH_2-S-(CH_2)_8\dot{P}_h;
                              -CH<sub>2</sub>CH<sub>2</sub>-NH-CH<sub>2</sub>-4-(4/Cl-Ph)-Ph;
                              -CH<sub>2</sub>CH<sub>2</sub>-NH-CH<sub>2</sub>-4-[4|CH<sub>3</sub>)2CHCH<sub>2</sub>-]-Ph;
                             -CH<sub>2</sub>CH<sub>2</sub>-NH-CH<sub>2</sub>-4-(4-CF<sub>3</sub>-Ph)-Ph;
                             -CH<sub>2</sub>CH<sub>2</sub>-S-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph;
                             -CH_2CH_2-S(O)-CH_2-4-(4-Cl-Ph)_TPh;
25
                             -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph;
                            -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S(O)-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph;
                            -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S-CH<sub>2</sub>-4-[3,4-di-Cl-PhCH<sub>2</sub>O-)-Ph;
```

--160--CH₂CH₂-NHSO₂-CH₂-4-[4-(4-Ph)-Ph]-Ph;
-CH₂CH₂CH₂-NHSO₂-CH₂-4-(4-Cl-Ph)-Ph;
-CH₂CH₂CH₂-NHSO₂-CH₂-4-(Ph-C≡C-)-Ph;
-CH₂CH₂CH₂-NHSO₂-4-(4-Cl-Ph)-Ph; and
-CH₂CH₂CH₂-NHSO₂-4-(naphth-2-yl)-Ph.

50. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of a compound of

formula I:

$$R^2 O$$
 NH
 O
 R^{13}
 R^{11}
 R^{12}
 R^{3}
 $R^{4}O$
 R^{5}
 R^{6}
 R^{5}
 R^{6}
 R^{13}
 R^{11}
 R^{12}
 R^{13}
 R^{11}
 R^{12}
 R^{13}
 R^{11}
 R^{12}
 R^{13}
 R^{12}

10 wherein

15

 R^1 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and $-R^a-Y-R^b-(Z)_x$; or a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$;

10

15

20

25

 R^2 is hydrogen or a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$;

 R^{3} is $-OR^{c}$, $-NR^{c}R^{c}$, $-O-R^{a}-Y+R^{b}-(Z)_{x}$, $-NR^{c}-R^{a}-Y-R^{b}-(Z)_{x}$, $-NR^{c}R^{c}$, or $-O-R^{c}$;

 R^4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, $-R^a-Y-R^b-(Z)_x$, $-C(O)R^d$ and a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$;

R⁵ is selected from the group consisting of hydrogen, halo,
-CH(R^c)-NR^cR^c, -CH(R^c)-NR^cR^e and -CH(R^c)-NR^c-R^a-Y-R^b-(Z)_x;

 R^6 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, $-R^a-Y-R^b-(Z)_x$, $-C(O)R^d$ and a saccharide group optionally substituted with $-NR^c-R^a-Y-R^b-(Z)_x$, or R^5 and R^6 can be joined, together with the atoms to which they are attached, form a heterocyclic ring optionally substituted with $-NR^c-R^a-Y-R^b-(Z)_x$;

 R^7 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, $-R^a-Y-R^b-(Z)_x$, and $-C(O)R^d$;

R⁸ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R⁹ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R¹⁰ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and

heterocyclic; or R^8 and R^{10} are joined to form $-Ar^1-O-Ar^2-$, where Ar^1 and Ar^2 are independently arylene or heteroarylene;

R¹¹ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic, or R¹⁰ and R¹¹ are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring;

 R^{12} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, $-C(O)R^d$, $-C(NH)R^d$, $-C(O)NR^cR^c$, $-C(O)OR^d$, $-C(NH)NR^cR^c$ and $-R^a-Y-R^b-(Z)_x$, or R^{11} and R^{12} are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring;

R¹³ is selected from the group consisting of hydrogen or -OR¹⁴;

R¹⁴ is selected from hydrogen -C(O)R^d and a saccharide group;

each Ra is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkynylene and substituted alkynylene;

bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene, provided R^b is not a covalent bond when Z is hydrogen;

each R^c is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and -C(O)R^d;

each R^d is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl,

10

5

15

10

15

20

25

--163-cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic: Re is a saccharide group; X^1 , X^2 and X^3 are independently selected from hydrogen or chloro; each Y is independently selected from the group consisting of oxygen, sulfur, -S-S-, $-NR^{c}-$, -S(O)-, $-SO_{2}-$, $-NR^{c}C(O)-$, $-OSO_{2}-$, -OC(O)-, $-NR^{c}SO_{2}-$, $-C(O)NR^{c}-$, -C(O)O-, $-SO_{2}NR^{c}-$, $-SO_{2}O-$, $-P(O)(OR^{c})O-$, $-P(O)(OR^c)NR^{c-}$, $-OP(O)(OR^c)O-$, $-OP(O)(OR^c)NR^{c-}$, -OC(O)O-, -NR°C(O)O-, -NR°C(O)NR°-, - ϕ C(O)NR°- and -NR°SO₂NR°-; each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic; n is 0, 1 or 2; x is 1 or 2; and pharmaceutically acceptable salts, stereoisomers and prodrugs thereof; provided that at least one of R, R², R³, R⁴, R⁵, R⁶, R⁷ or R¹² has a substitutent of the formula $-R^a - Y - R^b - (Z)_x$; and further provided that: when Y is $-NR^c \not\mid$, R^c is alkyl of 1/1 to 4 carbon atoms, Z is hydrogen (i) and R^b is alkylene, then R^b contains at least 5 carbon atoms; when Y is $-C(\phi)NR^{l_c}$, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;/ when Y is sulfur, /Z is hydrogen and Rb is alkylene, then Rb (iii) contains at least 7 carbon atoms; and when Y is oxygen, Z is hydrogen and Rb is alkylene, then Rb contains at least 11 carbon atoms. The pharmaceutical composition of Claim 50, wherein R¹ is a 51.

saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$.

52. The pharmaceutical composition of Claim 51, wherein R¹ is a saccharide group of the formula:

wherein

 R^{15} is $-R^a-Y-R^b-(Z)_x$ and

R¹⁶ is hydrogen or methyl.

53. The pharmaceutical composition of Claim 52, wherein R¹⁵ is a -R^a-Y-R^b-(Z)_x group selected from the group consisting of:

-CH₂CH₂-NH-(CH₂)₉CH₃;

-CH₂CH₂CH₂-NH/(CH₂)₈CH₃;

10 $-CH_2CH_2CH_2CH_2/NH-(CH_2)_7CH_3$;

-CH₂CH₂-NHSO (CH₂) CH₃;

 $-CH_2CH_2-NHSO(-(CH_2)_{11}CH_3)$;

 $-CH_2CH_2-S-(CH_2^{1})_8CH_3;$

 $-CH_2CH_2-S-(CH_2)_9CH_3;$

15 $-CH_2CH_2-S-(CH_2)_{10}CH_3$;

-CH₂CH₂CH₂-S-(CH₂)₈CH₃

-CH₂CH₂CH₂-S-(CH₂)₉CH₃;

 $-CH_2CH_2CH_2-S-(CH_2)_3-CH=CH-(CH_2)_4CH_3$ (trans);

 $-CH_{2}CH_{2}CH_{2}CH_{2}-S-(CH_{2})_{7}CH_{3};$

```
-CH<sub>2</sub>CH<sub>2</sub>-S(O)-(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>;
                          -CH_2CH_2-S-(CH_2)_6Ph;
                          -CH_2CH_2-S-(CH_2)_8Ph;
                          -CH_2CH_2CH_2-S-(CH_2)_8Ph;
                          -CH<sub>2</sub>CH<sub>2</sub>-NH-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph;
  5
                         -CH<sub>2</sub>CH<sub>2</sub>-NH-CH<sub>2</sub>-4-[4-CH<sub>3</sub>)<sub>2</sub>CHCH<sub>2</sub>-]-Ph;
                         -CH<sub>2</sub>CH<sub>2</sub>-NH-CH<sub>2</sub>-4-(4-CF<sub>3</sub>-Ph)-Ph;
                         -CH<sub>2</sub>CH<sub>2</sub>-S-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph;
                         -CH_2CH_2-S(O)-CH_2-4-(4^{\dagger}Cl-Ph)/Ph;
10
                         -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph;
                         -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S(O)-CH<sub>2</sub>-4/(4-Cl-Ph)-Ph;
                         -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S-CH<sub>2</sub>-4-[4,4-di-Cl-PhCH<sub>2</sub>O-)-Ph;
                         -CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>-CH<sub>2</sub>/4 [4-Ph)-Ph]-Ph;
                        -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>/CH<sub>2</sub>/4/(4-Cl-Ph)-Ph;
                        -CH_2CH_2CH_2-NHSO_2-CH_2/4-(Ph-C=C-)-Ph;
15
                      -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>-4/4-Cl-Ph)-Ph; and
                        -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>-4-(naphth-2-yl)-Ph.
```

- 54. The pharmaceutical composition of Claim 50, wherein R³ is -OH or -NR°R°.
- 55. The pharmaceutical composition of Claim 50, wherein R⁵ is hydrogen, -CH₂-N-(N-CH₃-D-glucamine); -CH₂-NH-CH₂CH₂-NH-(CH₂)₉CH₃; -CH₂-NH-CH₂CH₂-NH-(CH₂)₁₁CH₃; -CH₂-NH-(CH₂)₅-COOH; and -CH₂-N-(2-amino-2-deoxygluconic acid).
- 56. The pharmaceutical composition of Claim 50, wherein R⁸ is -CH₂C(O)NH₂, -CH₂COOH, benzyl, 4 hydroxyphenyl or 3-chloro-4-hydroxyphenyl.

10

- 57. The pharmaceutical composition of Claim 50, wherein R⁹ is hydrogen and R¹¹ is hydrogen or methyl.
- 58. The pharmaceutical composition of Claim 57, wherein R¹⁰ is alkyl or substituted alkyl.
- 59. The pharmaceutical composition of Claim 58, wherein R^{12} is hydrogen, alkyl, substituted alkyl or $-C(O)R^{d}$.
 - 60. The pharmaceutical composition of Claim 50, wherein n is 1.
 - 61. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of a compound of formula II:

HO
$$R^{21}$$
 R^{26} R^{26} R^{27} R^{22} R^{22} R^{23} R^{23} R^{24} R^{25} R^{27} R^{27}

wherein

10

15

20

25

 R^{21} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and $-R^a-Y-R^b-(Z)_x$; or a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$;

 R^{22} is $-OR^c$, $-NR^cR^c$, $-O-R^a + Y-R^b - (Z)_x$ or $-NR^c - R^a - Y - R^b - (Z)_x$; R^{23} is selected from the group consisting of hydrogen, halo,

 $-CH(R^c)-NR^cR^c$, $-CH(R^c)-R^c$ and $-CH(R^c)-NR^c-R^a-Y-R^b-(Z)_x$;

R²⁴ is selected from the group consisting of hydrogen and lower alkyl;

R²⁵ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R²⁶ is selected from the group consisting of hydrogen and lower alkyl; or R²⁵ and R²⁶ are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring;

 R^{27} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, $-C(O)R^d$, $-C(NH)R^d$, $-C(O)NR^cR^c$, $-C(O)OR^d$, $-C(NH)NR^cR^c$ and $-R^a-Y-R^b-(Z)_x$, or R^{26} and R^{27} are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring;

each R^a is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkynylene and substituted alkynylene;

each R^b is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene, provided R^b is not a covalent bond when Z is hydrogen;

15

20

25

each R^c is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and $-C(O)R^d$;

each R^d is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

Re is an aminosaccharide group;

each Y is independently selected from the group consisting of oxygen, sulfur, $-S-S-,-NR^c-$, -S(O)-, $-SO_2-$, $-NR^cC(O)-$, $-OSO_2-$, -OC(O)-, $-NR^cSO_2-$, $-C(O)NR^c-$, -C(O)O-, $-SO_2NR^c-$, $-SO_2O-$, $-P(O)(OR^c)O-$, $-P(O)(OR^c)NR^c-$, $-OP(O)(OR^c)NR^c-$, -OC(O)O-, $-NR^cC(O)O-$, $-NR^cC(O)NR^c-$, $-OC(O)NR^c-$, and $-NR^cSO_2NR^c-$;

each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic;

n is 0, 1 or 2;

x is 1 or 2:

and pharmaceutically acceptable salts, stereoisomers and prodrugs thereof; provided that at least one of R^{21} , R^{22} , R^{23} or R^{27} has a substitutent of the formula $-R^a-Y-R^b-(Z)_x$;

and further provided that:

- (i) when Y is -NR^c, R^c is alkyl of 1 to 4 carbon atoms, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;
- (ii) when Y is -C(O)NR^c-, Z is hydrogen and R^b is alkylene, then R^b contains at least 5 carbon atoms;
- (iii) when Y is sulfur, Z is hydrogen and R^b is alkylene, then R^b contains at least 7 carbon atoms; and

- (iv) when Y is oxygen, Z is hydrogen and R^b is alkylene, then R^b contains at least 11 carbon atoms.
- 62. The pharmaceutical composition of Claim 61, wherein R²¹ is a saccharide group of the formula:

wherein

5

15

 R^{15} is $-R^a-Y-R^b-(Z)_x$, and

R¹⁶ is hydrogen or methyl

63. The pharmaceutical composition of Claim 62, wherein R^{15} is a $-R^a-Y-R^b-(Z)_x$ group selected from the group consisting of:

10
$$-CH_2CH_2-NH-(CH_2)_9CH_3$$
;

-CH₂CH₂CH₂-NH-(CH₂)₈CH₃;

-CH₂CH₂CH₂CH₂-NH-(CH₂)₇CH₃;

-CH₂CH₂-NHSO₂-(CH₂)₉CH₃;

-CH₂CH₂-NHSO₂-(CH₂)₁₁CH₃;

$$-CH2CH2-S-(CH2)8CH3;$$

-CH₂CH₂-S-(CH₂)₉CH₃;

-CH₂CH₂-S-(CH₂)₁₀CH₃;

-CH₂CH₂CH₂-S-(CH₂)₈CH₃;

```
-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>;
                            -CH_2CH_2CH_2-S-(CH_2)_3-CH=CH-(CH_2)_4CH_3 (trans);
                           -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>;
                           -CH<sub>2</sub>CH<sub>2</sub>-S(O)-(CH<sub>2</sub>)<sub>9</sub>CH<sub>3</sub>;
    5
                           -CH_2CH_2-S-(CH_2)_6Ph;
                           -CH_2CH_2-S-(CH_2)_8Ph;
                           -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S-(CH<sub>2</sub>)<sub>8</sub>Ph;
                           -CH<sub>2</sub>CH<sub>2</sub>-NH-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph;
                           -CH<sub>2</sub>CH<sub>2</sub>-NH-CH<sub>2</sub>-4-[4-CH<sub>3</sub>)<sub>2</sub>CHCH<sub>2</sub>-]-Ph;
 10
                           -CH<sub>2</sub>CH<sub>2</sub>-NH-CH<sub>2</sub>-4-(4-C|<sub>73</sub>-Ph)-Ph;
                           -CH<sub>2</sub>CH<sub>2</sub>-S-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph;
                          -CH_2CH_2-S(O)-CH_2-4-(4-Cl_Ph)-Ph;
                          -CH<sub>2</sub>CH<sub>2</sub>-S-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph;
                          -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S(O)-CH<sub>2</sub>-4-(4-C1-Ph)-Ph;
                          -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-S-CH<sub>2</sub>-4-[3,4-di-Cl-PhCH<sub>2</sub>O-)-Ph;
 15
                          -CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>-CH<sub>2</sub>-4-[4/(4-Ph)-Ph]-Ph;
                          -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>-CH<sub>2</sub>-4-(4-Cl-Ph)-Ph;
                         -CH_2CH_2CH_2-NHSO_2-CH_2-4-(Ph_7C=C-)-Ph;
                         -CH<sub>2</sub>CH<sub>2</sub>-NHSO<sub>2</sub>-4/(4-Cl<sub>2</sub>Ph)-Ph; and
20
                         -CH2CH2CH2-NHSO2-4 (naphth-2-yl)-Ph.
```

- 64. The pharmaceutical composition of Claim 61, wherein R²² is -OH or -NR^cR^c.
- 65. The pharmaceutical composition of Claim 61, wherein R²³ is hydrogen, -CH₂-N-(N-CH₃-D-glucamine); -CH₂-NH-CH₂CH₂-NH-(CH₂)₉CH₃; -CH₂-NH-CH₂CH₂-NH-(CH₂)₁₁CH₃; -CH₂-NH-(CH₂)₅-COOH; or -CH₂-N-(2-NH-CH₂-NH-CH

amino-2-deoxygluconic acid).

- 66. The pharmaceutical composition of Claim 61, wherein R^{24} is hydrogen and R^{26} is hydrogen or methyl.
- 67. The pharmaceutical composition of Claim 66, wherein R²⁵ is alkyl or substituted alkyl.
- 5 68. The pharmaceutical composition of Claim 67, wherein R²⁵ is isobutyl.
 - 69. The pharmaceutical composition of Claim 68, wherein R^{27} is hydrogen, alkyl, substituted alkyl or $-C(G)R^d$.
 - 70. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of a compound shown in any of Tables I, II, III, IV, V or VI, or a pharmaceutically-acceptable salt thereof.
 - 71. A method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition of Claim 36, 50 or 61.